HIV-associated PML: Changing epidemiology and clinical approach

Cleveland Clinic Journal of Medicine

Volumn 78, Issue SUPPL. 2, 2011, Pages

  Simpson, David M ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIDS RELATED COMPLEX; ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INCIDENCE; JC VIRUS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VIROLOGY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; INCIDENCE; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

EID: 84859577916     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.78.s2.06     Document Type: Article

References (15)

1. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4:59-68.
2. Tagliati M, Simpson D, Margello S, Clifford D, Schwartz RL, Berger JR. Cerebellar degeneration associated with human immu-nodei ciency virus infection. Neurology 1998; 50:244-251.
3. Koralnik I, Wüthrich C, Dang X, et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57:576-580.
4. Clifford DB, Yiannoutsos C, Glicksman M, et al. HAART improves prognosis in HIV-associated progressive multifocal leuko-encephalopathy. Neurology 1999; 52:623-625.
5. Berger JR, Levy RM, Flomenhoff D, Dobbs M. Predictive factors for prolonged survival in acquired immunodei ciency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998; 44:341-349.
6. Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9(suppl 1):47-53.
7. Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36:1047-1052.
8. Hou J, Major EO. The efi cacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 1998; 4:451-456.
9. Aksamit A. Treatment of non-AIDS progressive multifocal leukoen-cephalopathy with cytosine arabinoside. J Neurovirol 2001; 7:386-390.
10. Hall C, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodei ciency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998; 338:1345-1351.
11. Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002; 16:1791-1797.
12. Gasnault J, Kousignian P, Kahraman M, et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocen-ter observational study with clinical and JC virus load monitoring. J Neurovirol 2001; 7:375-381.
13. Geschwind MD, Skolasky RI, Royal WS, McArthur JC. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neuro-virol 2001; 7:353-357.
14. Verma S, Cikurel K, Koralnik IJ, et al. Mirtazapine in progressive multifocal leukoencephalopathy. J Infect Dis 2007; 196:709-711.
15. Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identii cation and characterization of mel oquine efi cacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53:1840-1849.